Pepteligence
Share
Medical notice — For research and educational purposes only. Not medical advice. Consult a licensed physician before using any peptide or compound.

Sermorelin

gh-releaseanti-agingsleep
Regulatory status — Research use only — not approved for human use

Sermorelin is a 29-amino-acid synthetic analog of human growth hormone-releasing hormone (GHRH) that stimulates the anterior pituitary to secrete growth hormone [1]. It has an established diagnostic use for assessing growth hormone deficiency in children and has been studied in limited observational research as an adjunctive therapy in hypogonadal men [1] [2]. Evidence for athletic performance, body composition, or recovery applications in healthy adults is absent from the peer-reviewed literature; its use in those contexts reflects gray-market interest rather than clinical validation [3].

Evidence coverage

28/38 claims verified by independent fact-checker.

1 claim pending coverage
  • FDA prescribing-label data(1 claim)

Pepteligence regenerates entries quarterly and when new high-tier evidence appears.

Quick facts

Half-life
—
Typical dose
See research context
Route
subcutaneous
Frequency
[insufficient evidence in research packet — no Tier 1 or Tier 2 clinical trial data available for performance or body composition use]
Cycle length
—
Evidence strength
Animal models

Suggested labs for this peptide class — educational reference only; not medical advice.

TL;DR

  • Half-life: — — dosed —.
  • Administered via subcutaneous.
  • Evidence base: animal model studies.
  • Primary goals: gh-release, anti-aging, sleep.
EVIDENCE HIERARCHYRCTsObservationalAnimal studiesAnecdotal

Primarily animal data

How we evaluate evidence →

How it works

GHRH analogues stimulate pulsatile GH release from the pituitary, elevating IGF-1 and promoting fat oxidation.

Sermorelin is a 29-amino-acid synthetic analog of endogenous human growth hormone-releasing hormone (GHRH) that retains the full biological activity of the native peptide [1]. Both intravenous and subcutaneous administration specifically stimulate growth hormone secretion from somatotroph cells of the anterior pituitary [1]. Preliminary in vitro evidence suggests sermorelin may have additional biological activities beyond pituitary stimulation — for example, one in vitro study explored potential effects in glioma cell lines — though these findings have not been replicated or extended to human clinical contexts [10]. Expert commentary notes that growth hormone secretagogues such as sermorelin, by raising downstream IGF-1, have been proposed as adjunctive therapy for some symptoms of hypogonadism, though the mechanistic pathway in that clinical context remains incompletely characterized [11].

What the research says

Research summary content coming soon. Check the references section for indexed studies.

100%50%25%0%00h1t½0h2t½0h3t½0h4t½0h
Approximate plasma concentration over 4 half-lives (0h × 4 = 0h)

Protocol lifecycle

BeforeDuringAfter

Before — Pre-cycle readiness

Readiness checklist

Regulatory and eligibility
  • Verify WADA prohibited list status if you participate in tested sport — sermorelin is prohibited [4].
  • Confirm legal status in your jurisdiction before obtaining or using sermorelin.
Medical
  • Consult a licensed physician; diagnostic use at 1 mcg/kg IV is the only well-characterized clinical application in the available literature [1].
  • No evidence-based readiness criteria exist for performance or body composition use.
Product quality
  • Be aware that sermorelin has been identified in falsified injectable products in Europe [9]; source verification is critical.
  • Confirm that sermorelin use is permissible in your jurisdiction and athletic context; it is prohibited by WADA in elite sport [4].
  • No evidence-based pre-use laboratory or screening protocol has been established in the available literature for performance applications.

During — Active protocol

Protocol notice — The following describes common protocols reported in research and community sources. This is not medical advice. Dosing, frequency, and duration should be determined with a licensed physician familiar with peptide research.
  • Observational data in hypogonadal men on testosterone therapy suggest monitoring serum IGF-1 as a marker of pituitary response [2].
  • No clinical trial data exist to guide monitoring parameters or protocol adjustments in healthy adults.

After — Post-cycle

  • [insufficient evidence in research packet — no cycling, washout, or post-cycle guidance supported by Tier 1 or Tier 2 evidence]

Stacks it appears in

Sermorelin is typically used as a standalone compound. Stack data coming soon.

Related peptides

Other compounds indexed on Pepteligence that share research tags with Sermorelin. Educational context only.

Epitalon

Tier 3
anti-agingsleep

DSIP

Tier 2
sleep

CJC-1295

Tier 3
gh-release

Hexarelin

Tier 3
gh-release

Safety

Common side effects

  • ·[insufficient evidence in research packet — no adverse event data from human clinical trials available]

Rare side effects

  • ·[insufficient evidence in research packet]
Safety notice — Serious / theoretical risks:
  • [insufficient evidence in research packet — the clinical safety profile has not been established in the available evidence base]

Contraindications

  • ·Elite sport competition — sermorelin is prohibited by WADA [4] [5] [6].
  • ·No additional medical contraindications could be identified in the current research packet; the clinical safety profile is not established.

Community experiences

Community content — User-submitted experiences are self-reported and have not been verified. They do not constitute medical advice. Pepteligence aggregates community data under Section 230 protections.

No community experiences yet for Sermorelin. Be the first to share yours.

Share your experience →

Have you tried Sermorelin?

Share your protocol and outcome to help build the community dataset.

Share your experience →

Sermorelin — at a glance

PropertySermorelin—
Half-life——
Routesubcutaneous—
Typical doseSee research context—
MechanismSermorelin is a 29-amino-acid synthetic analog of endogenous human growth hormone-releasing hormone (GHRH) that retains the full biological activity of the native peptide. Both intravenous and subcutaneous administration specifically stimulate growth hormone secretion from somatotroph cells of the anterior pituitary. Preliminary in vitro evidence suggests sermorelin may have additional biological activities beyond pituitary stimulation — for example, one in vitro study explored potential effects in glioma cell lines — though these findings have not been replicated or extended to human clinical contexts. Expert commentary notes that growth hormone secretagogues such as sermorelin, by raising downstream IGF-1, have been proposed as adjunctive therapy for some symptoms of hypogonadism, though the mechanistic pathway in that clinical context remains incompletely characterized.—
Evidence strengthanimalanecdotal
Primary goalgh-release—

Frequently asked questions

What is Sermorelin?
Sermorelin is a 29-amino-acid synthetic analog of human growth hormone-releasing hormone (GHRH) that stimulates the anterior pituitary to secrete growth hormone. It has an established diagnostic use for assessing growth hormone deficiency in children. It is prohibited by WADA and lacks approval for performance or body composition applications.
How does Sermorelin work?
Sermorelin is a synthetic analog of endogenous human GHRH that retains the full biological activity of the native peptide. Both intravenous and subcutaneous administration specifically stimulate growth hormone secretion from somatotroph cells of the anterior pituitary via GHRH receptors.
What is Sermorelin approved for?
Sermorelin has an established diagnostic application for assessing growth hormone deficiency in children. It is not approved for body composition or performance enhancement. No Tier 1 or Tier 2 clinical trial data support its use for these non-diagnostic applications.
Is Sermorelin FDA-approved?
Sermorelin has been approved for the diagnostic assessment of growth hormone deficiency in children — a narrow, specific indication. It is not FDA-approved for body composition, anti-aging, or performance enhancement applications.
How is Sermorelin administered?
Sermorelin is administered subcutaneously. Both intravenous and subcutaneous administration have been shown to stimulate growth hormone secretion in research contexts.
What are common dosages of Sermorelin?
No consensus human dosing data have been established from clinical trial evidence for performance or body composition use. Its diagnostic dosing is established in that context but is not applicable to off-label or research use.
What are common side effects of Sermorelin?
Controlled clinical safety data for sermorelin use in performance or body composition contexts are not available in the current research literature. Side-effect characterization for these applications has not been established.
Is Sermorelin prohibited in sport?
Yes. Sermorelin is prohibited by the World Anti-Doping Agency (WADA). Athletes subject to anti-doping testing should not use sermorelin.
Is Sermorelin legal?
Sermorelin has a diagnostic approval in the United States but is not approved for performance enhancement or general therapeutic use. Its legal status for use outside its diagnostic indication varies by jurisdiction. This is not legal advice.
Can Sermorelin be combined with other compounds?
No evidence-supported combination protocols have been established for sermorelin in performance or body composition research contexts. No stacking combinations with human-validated data were identified in the current source literature.
How does Sermorelin differ from CJC-1295?
Both sermorelin and CJC-1295 are synthetic GHRH analogs that stimulate pituitary growth hormone secretion. Sermorelin is a 29-amino-acid peptide closely modeled on native GHRH with documented diagnostic applications in children. CJC-1295 incorporates a maleimido group enabling plasma protein binding and dramatically extended duration of action, but has no approved clinical use.
How does Sermorelin differ from Tesamorelin?
Both are synthetic GHRH analogs administered subcutaneously to stimulate pituitary growth hormone secretion. Tesamorelin is FDA-approved for reduction of visceral adipose tissue in HIV-infected adults with lipodystrophy and has a substantial controlled clinical evidence base for that indication. Sermorelin's approved use is diagnostic assessment of growth hormone deficiency in children.

References

  1. [1]

    Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.

    Prakash A, Goa K L

    BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 1999 · PMID 18031173

    View on PubMed →
  2. [2]

    Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.

    Sigalos John T, Pastuszak Alexander W, Allison Andrew et al.

    American journal of men's health · 2017 · PMID 28830317

    View on PubMed →
  3. [3]

    A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review.

    Coutinho Luis F D, DE Oliveira Neves Lucas F, Camilo Rafael P

    The Journal of sports medicine and physical fitness · 2026 · PMID 41880199

    View on PubMed →
  4. [4]

    Advances in the detection of growth hormone releasing hormone synthetic analogs.

    Memdouh Siham, Gavrilović Ivana, Ng Kelsey et al.

    Drug testing and analysis · 2021 · PMID 34665524

    View on PubMed →
  5. [5]

    Cationic exchange SPE combined with triple quadrupole UHPLC-MS/MS for detection of GHRHs in urine samples.

    Cristea Cătălina-Diana, Radu Mihai, Toboc Ani et al.

    Analytical biochemistry · 2023 · PMID 37806509

    View on PubMed →
  6. [6]

    Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.

    Uçaktürk Ebru, Nemutlu Emirhan

    Journal of pharmaceutical and biomedical analysis · 2026 · PMID 41138283

    View on PubMed →
  7. [7]

    Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.

    Thomas Andreas, Walpurgis Katja, Thevis Mario

    Journal of mass spectrometry : JMS · 2024 · PMID 38197510

    View on PubMed →
  8. [8]

    An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.

    Coppieters Gilles, Deventer Koen, Polet Michaël et al.

    Journal of pharmaceutical and biomedical analysis · 2022 · PMID 35298973

    View on PubMed →
  9. [9]

    Operation resistance: A snapshot of falsified antibiotics and biopharmaceutical injectables in Europe.

    Venhuis Bastiaan J, Keizers Peter H J, Klausmann Rüdiger et al.

    Drug testing and analysis · 2016 · PMID 26456392

    View on PubMed →
  10. [10]

    A potentially effective drug for patients with recurrent glioma: sermorelin.

    Chang Yuanhao, Huang Ruoyu, Zhai You et al.

    Annals of translational medicine · 2021 · PMID 33842627

    View on PubMed →
  11. [11]

    Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.

    Sinha Deepankar K, Balasubramanian Adithya, Tatem Alexander J et al.

    Translational andrology and urology · 2020 · PMID 32257855

    View on PubMed →
  12. [?]

    Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

    Mendias Christopher L, Awan Tariq M

    Sports medicine (Auckland, N.Z.) · 2026 · PMID 41966639

    View on PubMed →

Compare Sermorelin with…

Sermorelin vs Tesamorelin

Sermorelin · Tesamorelin

View comparison →